Axsome Therapeutics (AXSM) Gains from Sales and Divestitures (2021 - 2026)
Axsome Therapeutics recorded quarterly Gains from Sales and Divestitures of $286136.0 in Q1 2026, down 10.99% quarter-over-quarter from $321470.0 in Q4 2025, and up 17.13% year-over-year from $244299.0 in Q1 2025.
Axsome Therapeutics' Gains from Sales and Divestitures history runs 6 years deep, the most recent figure standing at $286136.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures rose 17.13% year-over-year to $286136.0; the TTM figure through Mar 2026 stood at $286136.0 (up 17.13% YoY), while the FY2025 annual figure was $321470.0, up 20.05% from the prior year.
- Gains from Sales and Divestitures came in at $286136.0 for Q1 2026 at Axsome Therapeutics, down from $321470.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $321470.0 in Q4 2025 to a low of $61581.0 in Q1 2022.
- A 5-year average of $196227.4 and a median of $210490.0 in 2024 frame the typical range for Gains from Sales and Divestitures.
- Across the five-year window, Gains from Sales and Divestitures surged 1854.33% in 2022 and grew 16.06% in 2025, its largest moves.
- Axsome Therapeutics' Gains from Sales and Divestitures stood at $81639.0 in 2022, then jumped by 138.15% to $194425.0 in 2023, then surged by 37.73% to $267779.0 in 2024, then advanced by 20.05% to $321470.0 in 2025, then declined by 10.99% to $286136.0 in 2026.
- According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $286136.0, $321470.0, and $295835.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 286,136.00 |
| Mar 31, 2026 | 286,136.00 |
| Dec 31, 2025 | 321,470.00 |
| Dec 31, 2025 | 321,470.00 |
| Sep 30, 2025 | 295,835.00 |
| Sep 30, 2025 | 295,835.00 |
| Jun 30, 2025 | 268,394.00 |
| Jun 30, 2025 | 268,394.00 |
| Mar 31, 2025 | 244,299.00 |
| Mar 31, 2025 | 244,299.00 |
| Dec 31, 2024 | 267,779.00 |
| Dec 31, 2024 | 267,779.00 |
| Sep 30, 2024 | 247,595.00 |
| Sep 30, 2024 | 247,595.00 |
| Jun 30, 2024 | 226,323.00 |
| Jun 30, 2024 | 226,323.00 |
| Mar 31, 2024 | 210,490.00 |
| Mar 31, 2024 | 210,490.00 |
| Dec 31, 2023 | 194,425.00 |
| Dec 31, 2023 | 194,425.00 |
| Sep 30, 2023 | 178,997.00 |
| Sep 30, 2023 | 178,997.00 |
| Jun 30, 2023 | 165,386.00 |
| Jun 30, 2023 | 165,386.00 |
| Mar 31, 2023 | 152,621.00 |
| Mar 31, 2023 | 152,621.00 |
| Dec 31, 2022 | 81,639.00 |
| Dec 31, 2022 | 81,639.00 |
| Sep 30, 2022 | 69,566.00 |
| Sep 30, 2022 | 69,566.00 |
| Jun 30, 2022 | 63,330.00 |
| Jun 30, 2022 | 63,330.00 |
| Mar 31, 2022 | 61,581.00 |
| Mar 31, 2022 | 61,581.00 |
| Dec 31, 2021 | 10,077.00 |
| Dec 31, 2021 | 10,077.00 |
| Sep 30, 2021 | 8,815.00 |
| Sep 30, 2021 | 8,815.00 |
| Jun 30, 2021 | 3,378.00 |
| Jun 30, 2021 | 3,378.00 |
| Mar 31, 2021 | 3,151.00 |
| Mar 31, 2021 | 3,151.00 |